Clarity Pharmaceuticals (CU6) AGM 2025 summary

Opening remarks and agenda

• Emphasis on teamwork, dedication, and achievements in advancing the product pipeline and manufacturing capabilities.

• Managing Director Michelle Parker led the Annual General Meeting on 25 November 2025, outlining progress and strategic direction.

Financial performance review

• Strong balance sheet reported after a $203 million capital raise at $4.20 per share to fund the development pipeline.

• Explanation of income tax expense due to U.S. subsidiary operations, despite unused tax losses.

Board and executive committee updates

• Re-election of directors Chris Roberts and Thomas Randahl discussed, highlighting their industry experience and contributions.

• Proxy advisors' recommendations and board's strong support for current directors addressed.

• The team expanded from 55 to 75 employees over the past year, with 57% based in Australia and 43% in the US.

• 70.7% of the team, one third of the Board, and a third of the Senior Executive Team are female.

• The management team brings expertise in corporate finance, clinical development, operations, and commercialisation.